Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | TDO2 | P48775 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3250625 | 0.83 | MAPT (0.40) | KDM4ESMN1; SMN2LMNATSHRMEN1 | |
| SCHEMBL28219643 | 0.83 | FABP7 (0.43) | LMNATSHRKMT2AALDH1A1L3MBTL1 | |
| SCHEMBL8559657 | 0.81 | MAPT (0.36) | KDM4ESMN1; SMN2LMNATSHRCYP1A2 | |
| SCHEMBL11386324 | 0.79 | P2RX4 (0.37) | KDM4ESMN1; SMN2LMNATSHRALDH1A1 | |
| SCHEMBL14921032 | 0.79 | EPHX2 (0.36) | SMN1; SMN2LMNAMEN1KMT2AMAPT | |
| SCHEMBL30805659 | 0.79 | EPHX2 (0.36) | SMN1; SMN2LMNAMEN1KMT2AMAPT | |
| SCHEMBL385982 | 0.76 | MAPT (0.40) | KDM4ESMN1; SMN2TSHRMEN1CYP2C19 | |
| SCHEMBL4372310 | 0.75 | LMNA (0.47) | KDM4ESMN1; SMN2LMNATSHRMEN1 | |
| SCHEMBL29539865 | 0.75 | LMNA (0.47) | KDM4ESMN1; SMN2LMNATSHRMEN1 | |
| SCHEMBL1286805 | 0.74 | MAPT (0.38) | KDM4ESMN1; SMN2LMNATSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114591212-A | Human plasma kallikrein inhibitors | 拜奥克里斯特制药公司 | 2022-06-07 | — | — | CN | disclosed |
| EP-2773619-A1 | NEW ARYL-QUINOLINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2014-09-10 | — | — | EP | disclosed |
| WO-2013064465-A1 | NEW ARYL-QUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-05-10 | — | — | WO | disclosed |
| CN-101466681-A | Tumor necrosis factor alpha inhibitors and their use in the treatment of human diseases | AVANIR PHARMACEUTICALS (US) | 2009-06-24 | — | — | CN | disclosed |
| EP-1996553-A2 | TUMOR NECROSIS FACTOR ALPHA INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES | Avanir Pharmaceuticals (US) | 2008-12-03 | — | — | EP | disclosed |
| WO-2007109251-A2 | TUMOR NECROSIS FACTOR ALPHA INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES | AVANIR PHARMACEUTICALS (US) | 2007-09-27 | — | — | WO | disclosed |
| US-7268164-B2 | Anti-epileptogenic agents | QUEENS UNIVERSITY AT KINGSTON (CA) | 2007-09-11 | — | — | US | disclosed |
| CN-1750823-A | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same | AVANIR PHARMACEUTICALS (US) | 2006-03-22 | — | — | CN | disclosed |
| US-6930112-B2 | Anti-epileptogenic agents | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2005-08-16 | — | — | US | disclosed |
| EP-1386166-A2 | ANTI-EPILEPTOGENIC AGENTS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2004-02-04 | — | — | EP | disclosed |
| US-20030229144-A1 | Anti-epileptogenic agents | QUEEN'S UNIVERSITY AT KINGSTON | 2003-12-11 | — | — | US | disclosed |
| US-20030194375-A1 | Administering 3-aminopropionic acid derivative as anticonvulsant | QUEEN'S UNIVERSITY AT KINGSTON AND NEUROCHEM, INC. | 2003-10-16 | — | — | US | disclosed |
| WO-2002073208-A2 | ANTI-EPILEPTOGENIC AGENTS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2002-09-19 | — | — | WO | disclosed |
| US-20020025949-A1 | Anti-epileptogenic agents | QUEEN'S UNIVERSITY AT KINGSTON | 2002-02-28 | — | — | US | disclosed |
| US-6306909-B1 | AMINOACID DERIVATIVES AND ESTERS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2001-10-23 | — | — | US | disclosed |
| EP-0969823-A2 | ANTI-EPILEPTOGENIC AGENTS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2000-01-12 | — | — | EP | disclosed |
| US-5874316-A | MEMBRANE COMPRISING TWO LAYERS, CLOSELY PACKED ARRAY OF AMPHIPHILIC MOLECULES AND PLURALITY OF GRAMICIDIN IONOPHORES COMPRISING MEMBRANE SPANNING SYSTEM, ATTACHED RECEPTOR MOLECULES; BINDING OF ANALYTE TO RECEPTOR CHANGES ION FLOW | AUSTRALIAN MEMBRANE BIOTECHNOLOGY RESEARCH INSTITUTE (AU) | 1999-02-23 | — | — | US | disclosed |
| WO-1998040055-A2 | ANTI-EPILEPTOGENIC AGENTS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 1998-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229144-A1 | Anti-epileptogenic agents | CA3, GAP43, GRIK5 | KDM4E 1626/4885SMN1; SMN2 2348/4885LMNA 2343/4885 |
| US-20030194375-A1 | Administering 3-aminopropionic acid derivative as anticonvulsant | SLC1A2, SLC1A1, SLC1A3 | KDM4E 1615/4885SMN1; SMN2 3205/4885LMNA 2739/4885 |
| US-20020025949-A1 | Anti-epileptogenic agents | CA3, GAP43, GRIK5 | KDM4E 1626/4885SMN1; SMN2 2348/4885LMNA 2343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.